OFFICE OF SCIENTIFIC AFFAIRS AND BIOTECHNOLOGY
INSTITUTIONAL BIOSAFETY COMMITTEE
Consistent with the National Institutes of Health "Guidelines for Research Involving Recombinant DNA Molecules" and the Centers for Disease Control-National Institutes of Health "Guidelines for Biosafety in Microbiological and Biomedical Laboratories," it is the policy of Downstate Medical Center that all uses of recombinant DNA molecules, all organisms and viruses containing recombinant DNA and all microbiological and biomedical uses of the Human immunodeficiency Viruses and other pathogens be reviewed and approved by the Institutional Biosafety Committee to insure that all applicable safety standards are met.
When a research project involves the use of recombinant DNA molecules or other pathogens, the Principal Investigator should submit their research protocols to the Institutional Biosafety Committee prior to the sponsor's deadline. Early submission of the protocol to the committee is advisable to allow time for any necessary clarification, revision and reconsideration and final approval.